Sign In
Free Newsletter
Excellus BCBS joins effort aimed at reducing insulin prices for diabetics
Excellus BCBS joins effort aimed at reducing insulin prices for diabetics
Excellus BlueCross BlueShield, the Blue Cross Blue Shield Association and other Blue Cross and Blue Shield companies joined Civica’s initiative to manufacture and distribute affordable insulins that, once approved, will be available to people living with diabetes at significantly lower prices than insulins currently on the market.
The medications are expected to be available to all consumers for $30 or less per vial starting in 2024.
Through the initiative, Civica will manufacture and distribute three analog insulins – glargine, lispro and aspart – which will be biosimilar drugs of the brand-name insulins Lantus, Humalog and Novolog. The insulins will be available in vials and prefilled pens at no more than $30 per vial or $55 for a box of five pens.
“We’re proud to be part of this national collaboration to bring more affordable insulin and other medications to our communities,” said Mona Chitre, chief pharmacy officer and vice president of Integrated Health Strategy for Excellus BCBS, in a statement. “The Civica initiative will help us fulfill our critical role of controlling rising health care costs while also ensuring that more patients take their medication as prescribed since their prescription drugs will now be more affordable.”
[email protected] / (585) 653-4021
